WuXi AppTec Co Ltd
SSE:603259
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
WuXi AppTec Co Ltd
Other Items
WuXi AppTec Co Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
WuXi AppTec Co Ltd
SSE:603259
|
Other Items
¥3.6B
|
CAGR 3-Years
135%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
J
|
Joinn Laboratories China Co Ltd
SSE:603127
|
Other Items
-¥275.6m
|
CAGR 3-Years
47%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Other Items
-¥1.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Other Items
-¥134.7m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Other Items
¥705.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Other Items
-¥1.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
Glance View
In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.
See Also
What is WuXi AppTec Co Ltd's Other Items?
Other Items
3.6B
CNY
Based on the financial report for Dec 31, 2025, WuXi AppTec Co Ltd's Other Items amounts to 3.6B CNY.
What is WuXi AppTec Co Ltd's Other Items growth rate?
Other Items CAGR 3Y
135%
The average annual Other Items growth rates for WuXi AppTec Co Ltd have been 135% over the past three years .